

Synthesis of (±)-phthalascidin 622

CHRISTIAN R. Razafindrabe^{1,2}, SYLVAIN Aubry², BENJAMIN Bourdon²,
MARTA Andriantsiferana¹, STEPHANE Pellet-Rostaing^{2,3*} & MARC Lemaire^{2*}

¹Laboratoire de Chimie des Produits Naturels et Biotechnologie (LPNB), Université d'Antananarivo,
17 Cité Mahatazana-Ampandrianomby, 101 Antananarivo, Madagascar, France

²ICBMS, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, CNRS, UMR5246,
Laboratoire de Catalyse et Synthèse Organique, 43 boulevard du 11 novembre 1918, Villeurbanne, F-69622, France

³ICSM, institut de Chimie Séparative de Marcoule, CNRS/CEA/UM2/ENSCM, UMR 5257, Laboratoire de Tri Ionique par des Systèmes
Moléculaires auto-assemblés, Bat 426, route de Marcoule, 30207 Bagnols sur Cèze, France

Received June 20, 2010; accepted July 21, 2010

A synthesis of functionalized phenolic α -amino-alcohols (±)-**8** and (±)-**16** as synthetic precursors of the catechol tetrahydroisoquinoline structure of phthalascidin 650 was disclosed. (±)-**8** was prepared in 5 steps from the commercially available sesamol. Starting from 3-methyl catechol **5**, 8 steps gave rise to the synthesis of phenolic α -amino-alcohol (±)-**16** in 27% overall yield. This synthetic strategy involved the elaboration of fully functionalized aromatic aldehyde **13** and its transformation into a phenolic α -amino-alcohol (±)-**16**, through a Knoevenagel condensation, simultaneous reduction of nitroketene and ester functions, and hydrogenolysis of the benzyl protecting group. The pentacycle (±)-**4** was obtained after 4 additional steps. The Pictet-Spengler cyclisation between the phenolic α -amino-alcohol (±)-**16** and the N-protected α -amino-aldehyde **4** allowed to obtain (1,3')-bis-tetrahydroisoquinoline **17** with N-methylated and N-Fmoc removed. The last step was a Swern oxidation allowing the expected intramolecular condensation.

phthalascidin, ecteinascidin, (1,3')-bis-tetrahydroisoquinoline, Pictet-Spengler, Bishler-Napieralsky

1 Introduction

The interest for the tetrahydroisoquinoline alkaloids is essentially aroused from their natural architectural complexity and their noteworthy biological properties as antitumor antibiotics [1]. The most active member of this family, Ecteinascidin 743 (**1**, Et 743), was isolated from the Caribbean tunicate *Ecteinascidia turbinata* [2–6] (Figure 1) and displayed highly potent cytotoxic activity against a variety of tumor cancer cells *in vitro* [7] and is approved for the treatment of soft tissue sarcoma under the brand name of Yondelis. The natural scarcity and potent medical use of Et 743 have attracted several groups to embark on its total synthe-

sis [8–12]. With regard to the structural complexity of Et 743 and its relative unstability in solution, synthetic phthalascidins analogues were envisaged. Thus, the synthesis and biological evaluation of Pt 650 **2** was first reported by Corey *et al.* [13–16] and exhibited similar biological activity to the natural product. A semi-synthetic route was achieved by Cuevas *et al.* [17, 18] through fermentation of the bacteria *Pseudomonas fluorescens* to produce cyanosafrafracin B (**3**) [19], an antibiotic of bacterial origin. However, since the discovery of Pt 650, several research groups were involved in the research of potentially more active structures, bearing a piperazine system [20–35]. The most impressive results were reported by Myers, with the discovery of a quinaldic acid derivative (QAD, **3**), exhibiting excellent antitumoral activity against a range of cancer cell lines *in vitro* [20, 22]. This group also described the synthesis of a

*Corresponding author (email: stephane.pellet-rostaing@cea.fr; marc.kmaire@univ-lyon.fr)




Figure 1 Ecteinascidin 743 (1), Phthalascidin 650 (2) and Cyanosafraicin B (3).

wide range of synthetic analogues using the solid supported chemistry [20, 21]. Spencer [23], Ong [24], Williams [25, 26], Liu [27, 28], Avendaño [29, 30], Echavarren [31], Kubo [32, 33] and Grieco *et al.* [34] were also involved in the synthesis and biological evaluation of simpler Et 743 synthetic analogues and obtained promising results.

In our previous communications, our ongoing project concerning the synthesis and biological evaluation of Pt 650 synthetic analogues [36–38], encouraged us toward the synthesis of the iminobenzazocine pentacyclic system contained in the Pt 650 starting from 3-methylcatechol **5** and sesamol **6**.

Herein, we report an efficient synthesis of the tetrahydroisoquinoline alkaloid (±)-phthalascidin 622 **4** (Figure 2) by Pictet-Spengler condensation involving N-protected α-amino-alcohol **12** and aminoalcohol **16**. After suitable modifications (nitrogen methylation and Fmoc deprotection, Swern oxidation), an intramolecular Strecker cyclisation from the 1,3'-bistetrahydroisoquinoline **17** could give rise to the formation of a (±)-Pt 650 analogue containing a methoxy group in place of the classical acetoxy group. As far as we know, the synthesis of this 16-[(1,3-dihydro-1,3-dioxo-2*H*-isoindol-2-yl)methyl]-6,6a,7,13,14,16-hexahydro-8-hydroxy-5,9-dimethoxy-4,10,17-trimethyl-7,13-imino-12*H*-1,3-dioxolo[7,8]isoquino[3,2-*b*][3]benzazocine (phthalascidin 622 (**4**)) was never described in literature, although its antitumor

efficiency has already been evaluated by Corey *et al.* [9].

2 Experimental

Starting materials were obtained from commercial suppliers and used without further purification. Solvents were distilled prior to use. Flash chromatographic purification was carried out on 230–400 mesh silica gel 60. NMR spectra were recorded on DRX 300 and 500 Brücker FT spectrometers. Abbreviation was used as: s (singlet), d (doublet), dd (divided doublet), t (triplet), q (quadruplet), m (multiplet).

5-Methoxybenzo[d][1,3]dioxole-5-carbaldehyde (**7**) [39]

To a stirring solution of sesamol **5** (25 g, 181 mmol) in acetone (400 mL) under Ar, was added K₂CO₃ (87.5 g, 633.5 mmol) and MeI dropwise (51.3 g, 362 mmol). The mixture was then stirred at room temperature for 24 h. The reaction mixture was filtered off and the solid washed with Et₂O (3 × 100 mL). The organic layer was washed successively with 1.5 N HCl (50 mL) and 1 N NaOH (50 mL), dried over MgSO₄ and evaporated. To a solution of 5.32 g of the pure 5-methoxybenzo[d][1,3]dioxole (35.11 mmol) in dry THF (21 mL), 2.5 M *n*-BuLi (35 mL, 86 mmol) in hexane was added at −20 °C. The mixture was stirred for 1 h, and then MeI (14.8 g, 105.34 mmol) in THF (21 mL) was added




Figure 2 Retrosynthetic analysis of Phthalascidin 622.

dropwise. After stirring for an additional time of 1 h, H₂O (100 mL) was added. The mixture was then extracted with ether (3 × 100 mL). The organic layers were washed with 1 N NaOH (150 mL), dried over MgSO₄ and evaporated. The crude residue was purified by flash column chromatography (silica gel, cyclohexane) to give the 5-methoxybenzo[d][1,3]dioxole intermediate (5.17 g, 89%). This compound (5 g, 30.1 mL) was dissolved in DMF and added to a solution of POCl₃ (4.2 mL, 45.2 mmol) preliminary added dropwise at 0 °C to a stirred anhydrous DMF (10 mL). The mixture was stirred at 100 °C for 3 h. Then a saturated NaHCO₃ aqueous solution (100 mL) was added at 0 °C and the aqueous layer was extracted with CH₂Cl₂ (3 × 50 mL). The organic layers were dried over MgSO₄ and evaporated. The residue was recrystallized from *n*-heptane to give **7** as colourless crystals (5.78 g, 85%). Mp 95–96 °C; ¹H NMR (300 MHz, CDCl₃) δ 10.19 (s, 1H, CHO), 7.11 (s, 1H, ArH), 6.03 (s, 2H, OCH₂O), 3.84 (s, 3H, OCH₃), 2.19 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃) δ 188.9, (CHO), 160.4, 153.0, 144.5, 123.5, 103.5 (ArC), 114.0 (ArCH), 102.5 (CH₂), 64.6 (OCH₃), 9.1 (CH₃). ESI-MS: *m/z* (%) = 194 [M]⁺ (100), 163 [M–CH₃OH]⁺ (21), 148 [M–OCH₃–CH₂]⁺ (54). Anal. calcd for C₁₀H₁₀O₄: C 61.85; 5.19%, found C 62.00; 5.25%.

(±)-2-Amino-3-(6-methoxy-7-methylbenzo[d][4,5]dioxol-5-yl)propan-1-ol (**8**) [40]

To a stirring solution of TiCl₄ (2.93 g, 15.46 mmol) in THF (10 mL), **7** (0.5 g, 2.58 mmol) in THF (4.5 mL) was added dropwise at –5 °C. After stirring at room temperature for 1 h, ethyl nitroacetate (0.595 g, 5.66 mmol) was added at –5 °C. Then, the mixture was stirred for an additional time of 1 h and *i*-Pr₂NEt (2.98 g, 23.17 mmol) was added. The mixture was then stirred at room temperature for 24 h and H₂O (20 mL) was added. The residue was extracted with CH₂Cl₂ (3 × 50 mL). The organic layer was washed with brine, dried over MgSO₄, evaporated and purified by flash chromatography (silica gel, cyclohexane/AcOEt) to yield a 50:50 mixture of (*E*):(*Z*) of the corresponding olefine as a yellow oil (0.79 g, 99%). Then, olefin intermediate (0.5 g, 1.618 mmol) was reduced with LiAlH₄ (614.2 mg, 16.18 mmol) in Et₂O (30 mL), under Ar. After stirring at room temperature for 4 h, CH₂Cl₂ (50 mL), H₂O (0.62 mL), 2N NaOH (0.62 mL) and H₂O (1.86 mL) were added at 0 °C until a white solid appeared. The mixture was then filtered and the solid washed with CH₂Cl₂, dried over MgSO₄, and evaporated to yield **8** as a pale yellow oil (352 mg, 91%). ¹H NMR (500 MHz, CDCl₃) δ 6.47 (s, 1H, ArH), 5.87 (s, 2H, OCH₂O), 4.55 (s, 1H, OH), 3.63 (s, 3H, OCH₃), 3.49 (dd, 1H, *J* = 11.0, 4.1 Hz, CH₂O), 3.33 (dd, 1H, *J* = 11.0, 6.0 Hz, CH₂O), 2.99 (s, 1H, CHN), 2.64 (m, 1H, CH₂CHN), 2.50 (m, 1H, CH₂CHN), 2.7 (br s, 2H, NH₂), 2.13 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃) δ 151.7, 145.4, 143.1, 123.5, 113.5, 107.0 (ArC), 101.1 (CH₂), 66.05 (CH₂), 61.01 (OCH₃), 53.98 (CH), 34.75 (CH₂), 9.47 (CH₃). ESI-MS: *m/z* (%) = 240 [M + H]⁺ (100),

179 [M–H₃NCHCH₂OH]⁺ (68). Anal. calcd for C₁₂H₁₇O₄N C 60.24; H 7.16; 5.85%, found C 60.11; H 6.98; N 5.73%.

9-((1,3-Dioxoisindolin-2-yl)methyl)-3-(6-methoxy-4-methyl-6,7-dihydro-[1,3]dioxolo[4,5-*h*]isoquinolin-7-yl)methyl-2-(1,3-dioxoisindolin-2-yl)acetate (**9**)

To a stirring solution of **8** (0.58 g, 2.43 mmol) in CH₂Cl₂ (42 mL) was added Et₃N (0.49 g, 4.85 mmol) and phthalylglycidyl chloride (1.30 g, 5.82 mmol) at 0 °C. The mixture was stirred 3 h at room temperature. The solution was then washed with 1.5 N HCl (10 mL), aqueous Na₂CO₃ (30 mL), brine, dried over Na₂SO₄, evaporated and purified by flash column chromatography (silica gel, cyclohexane/EtOAc, 94%). To the pure 2-(2-((1,3-dioxoisindolin-2-yl)acetamido)-3-(6-methoxy-7-methylbenzo[d][1,3]dioxol-5-yl)propyl-2-(1,3-dioxoisindolin-2-yl)acetate (1.30 g, 2.12 mmol) in CH₃CN (2.62 mL) was added dropwise POCl₃ (0.975 g, 6.36 mmol) at 0 °C and stirred and heated at 90 °C for 3 h. The reaction mixture was neutralized with a saturated Na₂CO₃ aqueous solution (15 mL) at 0 °C and the aqueous layer was extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, evaporated and purified by flash chromatography (silica gel, cyclohexane/AcOEt = 50:50 to 0:100) to yield **9** as a white solid (1.19 g, 95%). Mp 110–112 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.92 (m, 2H, *J* = 5.4, 3.0 Hz, 2ArH), 7.89 (m, 2H, *J* = 5.4, 3.0 Hz, 2ArH), 7.76 (m, 4ArH), 6.07 (d, 2H, *J* = 16.2 Hz, OCH₂O), 5.13 (dd, 1H, *J* = 17.6, 2.8 Hz, NCCH₂N), 4.78 (d, 1H, *J* = 17.7 Hz, NCCH₂N), 4.42 (d, 1H, *J* = 17.7 Hz, OCOCH₂N), 4.35 (d, 1H, *J* = 17.4 Hz, OCOCH₂N), 4.29 (m, 1H, *J* = 10.7, 4.7 Hz, CH₂OCO), 4.12 (m, 1H, *J* = 10.7, 8.0 Hz, CH₂OCO), 3.67 (s, 3H, CH₃), 3.57 (m, 1H, CHN), 2.93 (d, 1H, *J* = 15.8 Hz, CH₂CHN), 2.28 (m, 1H, CH₂CHN), 2.23 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃) δ 168.9 (CO), 167.7 (NCO), 167.3 (CN), 150.4, 146.2, 141.8, 132.8, 132.4, 121.0, 115.9 (ArC), 134.6, 134.2, 124.0, 123.7 (ArCH), 102.0 (OCH₂O), 68.9 (CH₂), 61.2 (OCH₃), 55.5 (CH), 43.5 (CH₂), 39.1 (CH₂), 22.7 (CH₂), 9.9 (CH₃). ESI-MS: *m/z* (%) = 596 [M + H]⁺ (100). HRMS (ESI) calcd for C₃₂H₂₆O₉N₃ [M + H]⁺ 596.1669, found 596.1670.

(1,3-Dioxo-1,3-dihydro-isindol-2-yl)acetic acid 9-(1,3-dioxo-1,3-dihydroisindol-2-yl-methyl)-5-methoxy-4-methyl-6,7,8,9-tetrahydro-[1,3]dioxolo[4,5-*h*]isoquinolin-7-yl-methyl ester (**10**)

A mixture of **9** (1 g, 1.68 mmol) and 10% Pd/C (0.358 mg, 0.337 mmol) in MeOH/CH₂Cl₂ (1:1.5 mL) was stirred for 24 h at room temperature under H₂ atmosphere (10 bars). Then, the residue was filtered through Celite, and dried over Na₂SO₄, evaporated and purified by flash chromatography (silica gel, cyclohexane/AcOEt 7:3) to yield **10** as a colourless solid (0.812 g, 81%). Mp 180 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.91 (m, 4H, 4ArH), 7.78 (dd, 2H, *J* = 5.5, 3.0 Hz, 2ArH), 7.75 (dd, 2H, *J* = 5.5, 3.0 Hz, 2ArH), 5.92 (s, 1H,

OCH₂O), 5.88 (s, 1H, OCH₂O), 4.60 (m, 1H, CHCH₂N), 4.52 (s, 1H, OCOCH₂N), 4.51 (s, 1H, OCOCH₂N), 4.45 (dd, 1H, *J* = 14.0, 4.3 Hz, CHCH₂N), 4.23 (m, 2H, CH₂OCOCH₂), 3.86 (dd, 1H, *J* = 14.0, 8.9 Hz, CHCH₂N), 3.77 (s, 3H, OCH₃), 2.87 (dd, 1H, *J* = 15.6, 2.8 Hz, CH₂CHN), 2.35 (m, 1H, CH₂CHN), 2.17 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃) δ 169.2 (CO), 167.8, 167.6 (NCO), 151.3, 144.9, 140.0, 132.5, 132.4, 121.4, 115.4, 112.6 (ArC), 134.7, 134.6, 124.0, 123.0 (ArCH), 101.2 (OCH₂O), 69.4, 42.7, 39.3, 27.1 (CH₂), 60.9 (OCH₃), 52.6, 51.7 (CH), 9.5 (CH₃). ESI-MS: *m/z* (%) = 598 [M + H]⁺ (100). HRMS (ESI) calcd for C₃₂H₂₇O₉N₃ [M + H]⁺ 598.1826, found 598.1825.

(±)-*N*-Fmoc-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)acetic acid 9-(1,3-dioxo-1,3-dihydroisoindol-2-yl-methyl)-5-methoxy-4-methyl-6,7,8,9-tetrahydro-[1,3]dioxolo[4,5-*h*]isoquinolin-7-yl-carbaldehyde (**12**)

A 15% by weight solution of Dess-Martin periodinane (670 mg, 0.237 mmol) in CH₂Cl₂ was added to a solution of the *N*-Fmoc α -amino-alcohol preliminary obtained from (±)-**11** (100 mg, 0.158 mmol) in CH₂Cl₂ (1 mL) at 0 °C. After stirring for 30 min at room temperature, the mixture was diluted with Et₂O (10 mL), and saturated solutions of Na₂S₂O₃ (5 mL) and NaHCO₃ (5 mL) were added. The resulting biphasic mixture was then stirred for 30 min, by which time both layers had become clear and colourless. After 20 min under stirring, the mixture was diluted with Et₂O (10 mL), and the organic layer separated, washed successively with NaHCO₃ (10 mL), H₂O (10 mL) and brine (10 mL), dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (SiO₂, cyclohexane/AcOEt = 80/20) to yield (±)-**12** as a white solid (79.7 mg, 80%). Mp 114 °C. *R*_f = 0.6 (cyclohexane/AcOEt = 50/50). ¹H NMR (500 MHz, DMSO-*d*₆, 80 °C) δ 9.57 (s, 1H, CHO), 7.84 (s, 6H, 6ArH), 7.60 (br s, 1H, 1ArH), 7.51 (d, 1H, *J* = 7.6 Hz, 1ArH), 7.41–7.37 (m, 2H, 2ArH), 7.31–7.27 (m, 2H, 2ArH), 5.91 (s, 1H, OCH_AH_BO), 5.64 (t, 1H, *J* = 7.2 Hz, CHCH₂N), 5.44 (s, 1H, OCH_AH_BO), 4.24 (m, 2H, OCH_AH_BCH and OCH_AH_BCH), 4.16 (m, 1H, OCH₂CH), 4.05 (m, 1H, CHCHO), 3.93 (m, 1H, CHCH_AH_BN), 3.87 (m, 1H, CHCH_AH_BN), 3.66 (s, 3H, OCH₃), 3.14 (m, 1H, *J* = 5.6, 15.4 Hz, CH_AH_BCHN), 2.86 (dd, 1H, *J* = 11.7, 15.4 Hz, CH_AH_BCHN), 2.09 (s, 3H, CH₃). ¹³C NMR (125 MHz, DMSO-*d*₆, 80 °C) δ 199.5 (CHO), 167.0 (3C, 3NCO), 155.3 (ArCO), 149.9 (ArCO), 144.2 (ArCO), 143.2 (ArC), 140.3 (2ArC), 138.7 (ArC), 134.1 (2ArCH), 131.1 (2ArC), 127.3 (2ArCH), 126.7 (2ArCH), 124.4 (2ArCH), 122.6 (2ArCH), 119.6 (2ArCH), 117.0 (ArC), 112.5 (ArC), 112.1 (ArC), 100.9 (OCH₂O), 66.2 (CH₂), 60.4 (CH and OCH₃), 48.1 (CH), 46.3 (CH), 41.5 (CH₂), 20.7 (CH₂), 8.5 (CH₃). ESI-MS: *m/z* (%) = 653 [M + Na]⁺ (33), 631 [M + H]⁺ (69), 453 [M + H – C₁₃H₉CH₂]⁺ (41), 409 [M + H – C₁₃H₉CH₂ – CO₂]⁺ (100), 391 [M + H – C₁₃H₉CH₂ – CO₂ – H₂O]⁺ (100). HRMS (ESI) calcd for C₃₇H₃₀N₂NaO₈ [M + Na]⁺ 653.1900, found 653.1901.

3-(Benzyloxy)-4-methoxy-5-methylbenzaldehyde (**13**)

To a solution of **5** (3.8 g, 15.74 mmol) in DMF/acetone 2/1 (50 mL) were added K₂CO₃ (6.55 g, 47.34 mmol) and BnBr (3 g, 17.52 mmol). After stirring at room temperature for 2 h, the reaction mixture was filtered and the solid washed with Et₂O (400 mL). The organic layer was washed with a 1.5 N HCl solution (100 mL). Then, the residue was extracted with Et₂O (3 × 150 mL), dried over MgSO₄, evaporated and purified by flash column chromatography (silica gel, cyclohexane/ethyl acetate = 8:2) to yield the corresponding 4-hydroxy-3-benzyloxy-5-methylphenol as an orange oil (5.5 g, 90%). This intermediate (5 g, 30.12 mmol) in AcOH (150 mL) and HMTA (10.54 g, 75.3 mmol) was stirred at 100 °C for 96 h. After this period, the solution was cooled and a saturated solution of NaHCO₃ was added. The aqueous layer was extracted with CH₂Cl₂ (3 × 50 mL). The organic layers were dried over MgSO₄, evaporated and purified by flash column chromatography (silica gel, cyclohexane) to give the corresponding 3-(benzyloxy)-4-hydroxy-5-methylbenzaldehyde in 90% yield (4.97 g), *R*_f = 0.3 (cyclohexane/AcOEt = 9:1). To a solution of pure 3-(benzyloxy)-4-hydroxy-5-methylbenzaldehyde (38.1 g, 0.196 mmol) in acetone (212 mL) were added K₂CO₃ (81.4 g, 0.589 mmol) and Me₂SO₄ (49.5 g, 0.393 mmol). After stirring at room temperature for 4 h, the reaction mixture was filtered and the solid washed with Et₂O. The organic layer was washed with a 1.5 N HCl solution (180 mL) and 1 N NaOH solution (200 mL). Then, the residue was extracted with Et₂O, dried over MgSO₄, evaporated and purified by flash column chromatography (silica gel, cyclohexane/AcOEt = 100:2 → 95:5) to yield **13** as a pale yellow oil (35.8 g, 88%). *R*_f = 0.6 (cyclohexane/AcOEt = 9:1). ¹H NMR (CDCl₃, 300 MHz) δ 9.75 (s, 1H, CHO), 7.20 (s, 1H, ArH), 7.19 (s, 1H, ArH), 4.56 (sept, 1H, *J* = 6.0 Hz, CH(CH₃)₂), 3.82 (s, 3H, OCH₃), 2.22 (s, 3H, CH₃), 1.31 (d, 6H, *J* = 6.0 Hz, CH(CH₃)₂). ¹³C NMR (CDCl₃, 75 MHz) δ 191.8 (CHO), 154.2 (ArC), 151.5 (ArC), 133.0 (ArCH), 132.3 (ArCH), 127.1 (ArC), 112.1 (ArC), 71.2 (CH(CH₃)₂), 60.5 (OCH₃), 22.4 (CH(CH₃)₂), 16.4 (CH₃). EI-MS: *m/z* (%) = 208 [M]⁺ (36), 166 [M – C₃H₆]⁺ (100), 165 [M – C₃H₇]⁺ (56), 151 [M – CH₃ – C₃H₆]⁺ (30), 123 [M – C₃H₆ – CH₃ – CO]⁺ (22). Anal. calcd for C₁₂H₁₆O₃ C 69.21; H 7.74 %, found C 69.03; H 7.93 %.

2-Amino-3-(3-(benzyloxy)-4-methoxy-5-methylphenyl)propan-1-ol (**15**)

To a stirring solution of TiCl₄ (2.66 g, 14.04 mmol) in THF (9 mL) was added dropwise at –5 °C **13** (0.6 g, 2.34 mmol) contained in THF (4.1 mL). After stirring at room temperature for 30 min, ethyl nitroacetate (0.685 g, 5.15 mmol) was added at –5 °C. Then, the mixture was stirred for an additional time of 30 min and *i*-Pr₂NEt (2.76 g, 21.09 mmol) was added. The mixture was then stirred at room temperature, stirring for 24 h and H₂O (20 mL) was added. The residue was extracted with CH₂Cl₂ (3 × 50 mL). The organic layers

were washed with brine, dried over MgSO_4 , evaporated and purified by flash column chromatography (SiO_2 , cyclohexane/ AcOEt = 100:0→90:10) to yield a 40:60 mixture of **14** as a yellow oil (0.64 g, 74 %). Nitroesters **14** (0.2 g, 0.539 mmol) was then reduced with LiAlH_4 (0.205 g, 5.39 mmol) in a stirring solution of Et_2O (12 mL), under an atmosphere of argon. After stirring at room temperature for 4 h, CH_2Cl_2 (25 mL), H_2O (0.2 mL), 2N NaOH (0.2 mL) and H_2O (0.6 mL) were added at 0 °C until a white solid appears. The mixture was then filtered and the solid washed with CH_2Cl_2 (3 × 30 mL). The filtrate was dried over Na_2SO_4 , evaporated to yield **15** as a pale yellow oil (151 mg, 93%). ^1H NMR (300 MHz, CDCl_3) δ 7.48 (d, 2H, J = 7.23 Hz, ArH), 7.42 (m, 2H, ArH), 7.35 (m, 1H, J = 7.3 Hz, ArH), 6.66 (s, 1H, ArH), 6.65 (s, 1H, ArH), 5.14 (s, 2H, CH_2), 3.87 (s, 3H, CH_3), 3.61 (dd, 1H, J = 10.8, 3.8 Hz, CH_AH_B), 3.38 (dd, 1H, 10.8, 7.0 Hz, CH_AH_B), 3.08 (m, 1H, CH), 2.94 (m, 1H, OH), 2.7 (dd, 1H, J = 13.6, 5.1 Hz, CH_CH_D), 2.43 (m, 1H, CH_AH_B), 2.29 (s, 3H, CH_3), 2.26 (br s, 2H, NH_2). ^{13}C NMR (125 MHz, CDCl_3) δ 152.0 (ArCO), 147.0 (ArCO), 137.6 (ArC), 134.3 (ArC), 132.5 (ArC), 128.9 (2C, ArCH), 128.3 (ArCH), 127.7 (2C, ArCH), 124.3 (ArCH), 113.5 (ArCH), 71.1 (CH_2), 66.7 (CH_2), 60.6 (OCH_3), 54.5 (CH), 40.9 (CH_2), 16.3 (CH_3). ESI-MS: m/z (%) = 302 [$\text{M} + \text{H}$] $^+$ (100), 272 [$\text{M} + \text{H} - \text{CH}_3\text{OH}$] $^+$ (21), 241 [$\text{M} + \text{H} - \text{H}_3\text{NCHCH}_2\text{OH}$] $^+$ (13). HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{23}\text{NO}_3\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 324.1576, found 324.1577. Anal. calcd for $\text{C}_{18}\text{H}_{23}\text{NO}_3$: C 71.73, H 7.69, N 4.65%, found C 71.54, H 7.80, N 4.52%.

(±)-5-(2-Amino-3-hydroxypropyl)-2-methoxy-3-methylphenol (**16**) [41]

A mixture of **15** (0.16 g, 0.532 mmol) and 10% Pd/C (64 mg), in 1:1 mixture of MeOH/ CH_2Cl_2 (9 mL), was stirred overnight at room temperature under 5 bars of H_2 atmosphere. After the catalyst was filtered and washed with MeOH, the filtrate was dried over Na_2SO_4 and evaporated to give **16** as a colourless oil (110 mg, 98%). ^1H NMR (CD_3OD , 500 MHz) δ 6.65 (d, 1H, J = 1.9 Hz, ArH), 6.6 (d, 1H, J = 1.0 Hz, ArH), 4.93 (s, 4H, NH_2 , ArCOH, OH), 3.77 (s, 3H, OCH_3), 3.71 (m, 1H, OCH_AH_B), 3.53 (dd, 1H, J = 11.7, 1.3 Hz, OCH_AH_B), 3.39 (br, 1H, CH), 2.79 (d, 2H, J = 7.5 Hz, CH_2CHN), 2.25 (s, 3H, CH_3). ^{13}C NMR (MeOH, 125 MHz) δ 150.4 (ArCO), 145.5 (ArCO), 132.1 (ArC), 132.0 (ArC), 122.5 (ArH), 115.0 (ArH), 60.9 (OCH_2), 59.4 (OCH_3), 54.8 (CH), 35.3 (CH_2CHN), 15.0 (CH_3). ESI-MS: m/z (%) = 212 [$\text{M} + \text{H}$] $^+$ (100), 151 [$\text{M} + \text{H} - \text{H}_3\text{NCHCH}_2\text{OH}$] $^+$ (40). HRMS (EI) calcd for $\text{C}_{11}\text{H}_{17}\text{O}_3\text{N}$ [M] $^+$ 211.1208, found 212.1207.

(7S,9R)-(9H-Fluoren-9-yl)methyl 9-((1,3-dioxoisindolin-2-yl)methyl)-7-((1R,3S)-8-hydroxy-3-(hydroxymethyl)-7-methoxy-2,6-dimethyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methoxy-6,7-dihydro-[1,3] dioxolo[4,5-h]isoquinoline-8(9H)-carboxylate (**17**)

A mixture of aldehyde **12** (550 mg, 0.873 mmol) and

(±)-5-(2-amino-3-hydroxypropyl)-2-methoxy-3-methylphenol **16** (368 mg, 1.74 mmol) in 7:3 mixture of toluene/TFA (4.7 mL), was stirred overnight at 80 °C. Then, the reaction mixture was neutralized with a saturated Na_2CO_3 aqueous solution (15 mL) at 0 °C and the aqueous layer was extracted with CH_2Cl_2 (3 × 100 mL). The organic layers were dried over Na_2SO_4 , evaporated and purified by flash column chromatography (silica gel, cyclohexane/ AcOEt = 90:10→40:60) to yield the regioisomers **17** and **18**, bis-1,3'-tetrahydroisoquinolines as a brown oil. **17** (210 mg, 33%), R_f = 0.3, **18** (130mg, 18%), R_f = 0.2 (cyclohexane/ AcOEt = 50/50). ^1H NMR (CDCl_3 , 300 MHz) δ 7.80 (m, 2H, 2ArH), 7.7 (m, 4H, 4ArH), 7.53 (m, 1H, 1ArH), 7.35 (m, 3H, 3ArH), 7.26 (s, 2H, 2ArH), 6.50 (s, 1H, ArH), 6.35 (m, 1H, CHCH_2N), 6.22 (s, 1H, $\text{OCH}_A\text{H}_B\text{O}$), 5.96 (m, 1H, CHCHCN), 5.84 (s, 1H, $\text{OCH}_A\text{H}_B\text{O}$), 5.65 (s br, 2H, OH and NH), 5.56 (s, 1H, ArOH), 5.11 (m, 1H, CHCH_2O) 4.57 (d, 1H, J = 6.4 Hz, CHCHCN), 4.22 (m, 2H, $\text{OCH}_A\text{H}_B\text{CH}$ and $\text{OCH}_A\text{H}_B\text{CH}$), 4.04 (m, 2H, CHCH_2N), 3.76 (s, 6H, 2 OCH_3), 3.73 (m, 2H, OCH_AH_B and OCH_AH_B), 3.57 (m, 1H, CH), 3.46 (m, 2H, CH_2CHN), 2.54 (m, 1H, $\text{CH}_A\text{H}_B\text{CHN}$), 2.26 (s, 3H, CH_3), 2.21 (m, 1H, $\text{CH}_A\text{H}_B\text{CHN}$), 2.08 (s, 3H, CH_3).

(7S,9R)-(9H-Fluoren-9-yl)methyl 9-((1,3-dioxoisindolin-2-yl)methyl)-7-((1R,3S)-8-hydroxy-3-(hydroxymethyl)-7-methoxy-2,6-dimethyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methoxy-4-methyl-6,7-dihydro-[1,3]dioxolo[4,5-h]isoquinoline-8(9H)-carboxylate (**19**)

17 (110 mg, 0.13mmol) was dissolved in 8:9 mixture of $\text{CH}_2\text{O}/\text{HCO}_2\text{H}$ (1.7 mL) and stirred under atmosphere of argon at 70 °C. After 23 h the reaction mixture was basified with NaHCO_3 (100 mL) aqueous solution at 0 °C, extracted with DCM. The combined organic layers were dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (SiO_2 , cyclohexane/80:20→50:50) to give rise the protected amine **19** (95 mg, 62%). R_f = 0.6 (cyclohexane/ ACOEt = 5:5). ^1H NMR (CDCl_3 , 300 MHz) δ 7.80 (m, 4H, 4ArH), 7.70 (m, 2H, 2ArH), 7.58 (m, 1H, ArH), 7.49 (m, 2H, ArH), 7.41 (m, 2H, ArH), 7.26 (s, 1H, ArH), 6.55 (s, 1H, ArH), 6.06 (m, 1H, CHCH_2N), 5.66 (s, 1H, $\text{OCH}_A\text{H}_B\text{O}$), 5.46 (s, 3H, NCH_3), 4.90 (s, 1H, $\text{OCH}_A\text{H}_B\text{O}$), 4.70 (s br, 1H, ArOH), 4.65 (s br, 1H, OH), 4.45 (m, 1H, CHCHCN) 4.42 (m, 1H, CHCH_2O), 4.19 (m, 1H, $\text{OCH}_A\text{H}_B\text{CH}$) 4.13 (m, 1H, $\text{OCH}_A\text{H}_B\text{CH}$), 4.08 (d, 1H, J = 6.4 Hz, CHCHCN), 3.98 (m, 2H, CHCH_2N), 3.82 (s, 3H, OCH_3), 3.57 (s, 3H, OCH_3), 3.45 (m, 2H, OCH_AH_B and OCH_AH_B), 3.23 (m, 1H, CH), 2.90 (m, 1H, $\text{CH}_A\text{H}_B\text{N}$), 2.60 (m, 1H, $\text{CH}_A\text{H}_B\text{CHN}$), 2.35 (m, 1H, $\text{CH}_C\text{H}_D\text{CHN}$), 2.27 (s, 3H, CH_3), 2.17 (m, 1H, $\text{CH}_C\text{H}_D\text{CHN}$), 2.01 (s, 3H, CH_3). ^{13}C NMR (75 MHz, CDCl_3): δ 167.6 (NCO), 157.2 (NCO), 150.4 (ArC), 150.0 (ArC), 146.8 (ArC), 144.7 (ArC), 143.6 (ArC), 141.4 (ArC), 141.2 (ArC), 139.3 (ArC), 137.6 (ArC), 133.9 (ArCH), 132.4 (ArCH), 131.8 (ArCH), 131.3 (ArC), 130.5 (ArC), 130.0 (ArCH), 128.2 (2ArCH), 128.1 (2ArCH),

127.8 (ArC), 127.7 (ArCH), 127.2 (ArC), 125.5 (ArC), 123.2 (ArCH), 120.3 (ArC), 120.0 (ArCH), 119.9 (ArCH), 114.2 (ArCH), 113.1 (ArC), 112.8 (ArC), 100.9 (OCH₂O), 69.0 (CH), 63.8 (OCH₂), 63.7 (CH₂), 61.1 (OCH₃), 59.9 (NCH₃, OCH₃), 47.8 (2CH), 47.1 (CH), 39.8 (CH₂), 31.8 (CH₂), 26.8 (CH₂), 15.8 (CH₃), 9.0 (CH₃). ESI-MS: m/z (%) = 838 [M + H]⁺ (100), 837 [M + 2H]⁺ (51).

2-(((7*S*,9*R*)-7-((1*R*,3*S*)-8-Hydroxy-3-(hydroxymethyl)-7-methoxy-2,6-dimethyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methoxy-4-methyl-6,7,8,9-tetrahydro-[1,3]dioxolo[4,5-*h*]isoquinolin-9-yl)methyl)isoindoline-1,3-dione (**20**)

To a solution of **19** (210 mg, 0.25 mmol) in DCM (0.84 mL) was added DBU (49 μ L) under atmosphere of argon. After stirring at room temperature for 30 min, the reaction mixture was dissolved in DCM (20 mL) and washed respectively with water and brine. The organic layer was then dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (SiO₂, DCM/ MeOH 100:00 $\rightarrow$ 90:10) to give **20** as a brown solid (150 mg, 97%). R_f = 0.5 (DCM/MeOH = 90:10). ¹H NMR (CDCl₃, 500 MHz) δ 7.84 (dd, 1H, J = 5.4, 3.0 Hz, ArH), 7.74 (dd, 1H, J = 5.5, 3.0 Hz, ArH), 7.70 (dd, 1H, J = 5.4, 3.0 Hz, ArH), 7.68 (dd, 1H, J = 5.4, 3.1 Hz, ArH), 7.26 (s, 1H, ArH), 6.65 (d, 1H, J = 9.3 Hz, OCH_AH_BO), 5.83 (d, 1H, J = 16.6 Hz, OCH_AH_BO), 5.82 (s, 1H, ArOH), 4.59 (m, 1H, CHCH₂N), 4.51 (s br, 1H, OH), 4.4 (m, 1H, CHCH_AH_BN), 4.0 (s br, 1H, NH), 3.95 (m, 1H, CHCH_AH_BN), 3.79 (m, 1H, CH_AH_BOH), 3.71 (m, 1H, CH), 3.57 (s, 1H, CH), 3.55 (s, 3H, OCH₃), 3.44 (dd, 1H, J = 10.9, 2.5 Hz, CH_AH_BOH), 3.41 (s, 3H, OCH₃), 3.15 (m, 1H, CH), 3.07 (dd, J = 16.4, 3.4 Hz, CH_AH_BCHN), 2.52 (dd, J = 15.3, 4.1 Hz, CH_AH_BCHN), 2.46 (s, 3H, NCH₃), 2.43 (m, 1H, CH_AH_BCHN), 2.2 (m, 1H, CH_AH_BCHN), 2.14 (s, 3H, CH₃), 2.08 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃): δ 168.8 (NCO), 168.0 (NCO), 151.0 (ArC), 150.8 (ArC), 145.9 (ArC), 143.6 (ArC), 139.4 (2ArC), 139.3 (ArC), 133.9 (ArCH), 133.5 (ArCH), 131.9 (2ArC), 123.3 (ArCH), 123.1 (ArCH), 120.9 (ArCH), 120.8 (ArC), 120.7 (ArC), 112.2 (ArC), 112.1 (ArC), 101.0 (OCH₂O), 64.2 (CH), 63.6 (OCH₂), 60.1 (OCH₃), 59.9 (NCH₃, OCH₃), 52.5 (CH), 49.0 (CH), 45.7 (CH), 39.6 (CH₂), 31.7 (CH₂), 26.6 (CH₂), 15.6 (CH₃), 8.9 (CH₃). ESI-MS: m/z (%) = 616 [M + H]⁺ (100), 617 [M + 2H]⁺ (35). HRMS (EI) calcd for C₃₄H₃₈O₈N₃ [M]⁺ 616.2659, found 616.2659.

Phthalascidin 622 (**4**)


DMSO (571 mg, 7.32 mmol) was added to the stirring solution of (COCl)₂ (929 mg, 7.32 mmol) in DCM (20 mL), at -60 °C. After stirring for 30 min, the amine **20** (150 mg, 0.244 mL) dissolved in DCM (6 mL) was added at -60 °C. Then the reaction mixture was stirred for an additional time of 30 min at -60 °C and *i*-Pr₂NEt (1.6 g, 12.19 mmol) was added. The mixture was stirred for 1 h at room temperature and TMSCN (474 mg, 4.78 mmol) was added dropwise.

After stirring overnight at room temperature, the reaction mixture was washed with water (3 $\times$ 50 mL) and brine, dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (SiO₂, cyclohexane/AcOEt 100:00 $\rightarrow$ 00:100 then MeOH) to yield the phenol **4** as a brown solid (40 mg, 27%). R_f = 0.3 (DCM/MeOH = 86:14). ¹H NMR (CDCl₃, 500 MHz) δ 7.73 (m, 2H, 2ArH), 7.68 (m, 2H, 2ArH), 6.41 (s, 1H, ArH₁₅), 5.75 (s, 1H, ArOH), 5.54 (s, 1H, OCH_AH_BO), 5.04 (s, 1H, OCH_AH_BO), 4.23 (s, 1H, H₁₂), 4.19 (d, 1H, J = 8.2 Hz, H₁), 4.11 (s, 1H, H₁₁), 3.74 (s, 3H, OMe₁₇), 3.71 (s, 3H, OMe₅), 3.60 (m, 2H, H₂₂ and H_{22'}), 3.36 (d, 1H, J = 7.5 Hz, H₁₃), 3.21 (m, 2H, H₃ and H₄), 3.07 (dd, 1H, J = 7.6, 18.1 Hz, H_{14'}), 2.62 (d, 1H, J = 19.9 Hz, H₁₄), 2.31 (s, 3H, NMe), 2.24 (s, 3H, Me₁₆), 2.08 (s, 3H, Me₆), 1.84 (m, 1H, H₄). ¹³C NMR (125 MHz, CDCl₃): δ 168.4 (2NCO), 150.4 (ArCOMe₁), 146.9 (ArCOH), 144.5 (ArCO), 142.9 (ArCOMe₂), 139.8 (ArCO), 134.1 (2ArCH), 132.3 (2ArC), 131.3 (ArC), 128.9 (ArC), 123.5 (2ArCH), 121.3 (ArC), 121.2 (ArCH), 118.7 (CN), 116.9 (ArC), 113.9 (ArC), 112.6 (ArC), 101.2 (OCH₂O), 61.4 (OMe), 61.1 (OMe), 61.0 (CH), 58.1 (CH), 57.0 (CH₂), 55.9 (CH₃), 55.6 (CH), 42.9 (CH₂), 42.2 (NMe), 26.5 (CH₂), 25.9 (CH₂), 16.4 (Me), 9.7 (Me). ESI-MS: m/z (%) = 623 [M + H]⁺ (100), 624 [M + 2H]⁺ (33). HRMS (EI) calcd for C₃₅H₃₅O₇N₄ [M]⁺ 623.2506, found. 623.2510.

3 Results and discussion

N-protected α -amino-alcohol **13** was obtained from the aminoalcohol **8**. Starting from the commercially available sesamol **6**, methylation of the hydroxyl group with MeI in a suspension of K₂CO₃ in acetone as a base followed by a selective *ortho*-lithiation in THF using *n*-BuLi at -20 °C, and methylation with MeI, allowed the formation of the corresponding methylated intermediate in 86% yield over two steps. The Vilsmeier-Haack formylation of this derivative with POCl₃ in DMF at 100 °C gave rise to aldehyde **7**, which was purified by recrystallisation in 99% yield [42]. Aldehyde **7** was then engaged in a Knoevenagel condensation with ethyl nitroacetate in THF, in the presence of TiCl₄ and *i*-Pr₂NEt, to afford the corresponding nitroalkene in 99% yield as a 1:1 mixture of *E/Z* isomers [43–45]. Then, the simultaneous reduction of the carbon-carbon double bond, ester and nitro functions was accomplished by LiAlH₄ in Et₂O in 91% yield, giving the racemic α -amino-alcohol **8** used in the next step without further purification. Compound **8** was obtained in 77% overall yield after five synthetic steps, with only two silica gel chromatography purification.



Acylation of both alcohol and amine reactive sites of **8** with phthaloyl glycine chloride [46, 47] in CH₂Cl₂, in the presence of NEt₃, provided the corresponding diprotected intermediate. The latter was then converted into the corresponding

Scheme 1 Synthesis of α -amino-alcohol **8**.

tetrahydroisoquinoline **10** through a Bischler-Napieralski reaction with POCl_3 in DMF which proceeded in 95% yield [48, 49], followed by a highly diastereoselective hydrogenation of the dihydroisoquinoline **9**. Indeed, reduction of the imine function by H_2 in the presence of 20% Pd/C in a 1:1 mixture of MeOH/ CH_2Cl_2 proceeded smoothly, to give racemic α -amino-ester *cis*-**10** in 81% yield with a diastereoisomeric excess of 96%, determined by ^1H NMR of the crude reaction mixture. The α -amino-ester *cis*-**10** was then transesterified in a 1:1 mixture of MeOH/ CH_2Cl_2 in the presence of MeONa, providing the α -amino-alcohol *cis*-**11** in 63% yield. The *cis*-configuration of **11** was determined on the basis of the 500 MHz NOESY spectrum analysis from the correlation analysis of the cross peak protons between H-1 and H-3. The amino group of ($\pm$)-**11** was consequently protected with

9-fluorenylmethyl pentafluorophenyl carbonate in DMF, affording the corresponding *N*-protected α -amino-alcohol in 89% yield. Subsequent oxidation of the hydroxyl group of this derivative in the presence of Dess-Martin periodinane reagent [50, 51] in CH_2Cl_2 gave rise to the formation of the chemically stable aldehyde ($\pm$)-**12** in 80% yield [38].

Then, we focused on the synthesis of a phenolic α -amino-alcohol synthetic precursor **16** (Scheme 3) which could be readily accessible and compatible for the stereoselectivity and regioselectivity of the Pictet-Spengler cyclization [25, 52, 53]. The synthesis of phenolic α -amino-alcohol **16** has been conducted in 6 steps of classical chemical transformations with an overall yield of 57%. Regioselective benzylation of the less hindered hydroxyl group of the commercially available 3-methylcatechol **5**, followed by Duff formylation

Scheme 2 Synthesis of *N*-protected α -amino-aldehyde **12**.Scheme 3 Synthesis of phenolic α -amino-alcohol **16**.


[54, 55] and *O*-methylation of the residual hydroxy group gave **13** in a 85% global yield. Knoevenagel condensation [43] of **13** with ethyl nitroacetate gave **14** in a 1:1 mixture of *E/Z* nitroketene derivative. Compound **14** was then reduced with LiAlH_4 to afford the corresponding racemic α -amino-alcohol **15** in 93% yield. Finally, hydrogenolysis of the benzyl group of **15** was realized in presence of Pd/C under 5 bar of H_2 in a 1:1 mixture of MeOH/ CH_2Cl_2 , to obtain the corresponding phenol **16** in 98% yield.

The iminobenzazocine pentacyclic system **21** was finally obtained in four steps from the preliminary Pictet-Spengler condensation of the diastereoisomer **12** with the racemic amino-alcohol **16** (Scheme 4). Cyclisation was performed at 80 °C in a 85:15 mixture of toluene/TFA [56, 57] to give a mixture of (1, 3')-bistetrahydroisoquinolines as two regioisomers **17** and **18**, respectively in 33% and 18% yields. The regioisomer **17** arises from cyclization *ortho*- to the 3-phenolic group of **16**, and **18** from cyclization *para*- to the same 3-phenolic group. The complete stereochemical assignments of (1,3')-bistetrahydroisoquinolines was achieved by NMR. Structural elucidation of **17** and **18** was made by 2D NMR (HSQC, COSY, HMBC and NOESY techniques). Moreover, **17** and **18** were obtained as mixtures of two diastereoisomers. The *cis* configuration of diastereoisomers **17** and **18** was determined on the basis of the 500 MHz NOESY spectrum analysis from a correlation analysis of the cross-peak protons between H-1 and H-3'. After methylation of the secondary amine of **17** in the Escweiler Clarke conditions ($\text{HCO}_2\text{H}/\text{HCOH}$, 2:1.7), the cleavage of the *N*-Fmoc group of **19** occurred by treatment with DBU affording the amine

20 in 67% yield. Finally, **4** was obtained in 72% yield by an intramolecular Stecker reaction based on the Swern oxidation of the primary alcohol of **20** followed the treatment of the corresponding hemiaminal formed *in situ* with TMSCN.

High-resolution EIMS of ($\pm$)-ptalascidin 622 4 demonstrated a molecular composition of $\text{C}_{35}\text{H}_{35}\text{O}_7\text{N}_4$ ($\text{M} + \text{H}$)⁺ by observation of the peak at a m/z 623.2510 (Δ -0.4 mmu). The lack of published data for **4** frustrated our attempts to identify our sample by simple comparison of NMR data. Therefore, extensive analyses of spectral data were necessary to confirm the structure. All protons and carbons were assigned by NMR experiments including COSY, HSQC, HMBC and NOESY techniques (Figures 3 and 4).

More especially, the resonance signal of the residual aromatic proton H_{15} was located at 6.41 ppm based on the cross peaking correlation with H_{14} , $\text{H}_{14'}$ and Me_{16} resonance signals identified from the COSY and NOESY spectra and located at 2.24 ppm, 2.62 ppm and 3.07 ppm respectively. From these hypotheses, OMe_{17} was characterized by a singlet at 3.74 ppm which was confirmed by a NOESY cross peaking correlation with the OH group at 5.75 ppm. COSY experiment allowed us to assign all of the resonance signals to the corresponding protons and the proposed stereochemistry of **4** was confirmed by NOESY experiment, especially for the *cis* position of H_4 , H_3 and H_{11} as well as the *anti* position of H_{12} towards H_1 and H_{13} which is also in *anti* with $\text{H}_{14'}$. HSQC experiment allowed us to attribute all of the primary, secondary and tertiary carbons. Finally, resonance signals of the quaternary carbons were deduced from the HMBC experiment.



Scheme 4 Synthesis of ($\pm$)-Pt 622 4.




Figure 3 ^1H NMR spectrum of **4** (CDCl_3).




Figure 4 2D COSY and NOESY spectra of **4** (CDCl_3).

4 Conclusion

To conclude, a practical synthesis of fully functionalized phenolic α -amino-alcohol ($\pm$)-**16** which constitutes the catechol aromatic fragment of the tetrahydroisoquinoline of ($\pm$)-Pt 622, has been synthesized in six steps from 3-methyl catechol **5** with an overall yield of 57%. After four additional steps involving a Pictet-Spengler condensation from

the synthetic precursors ($\pm$)-**12** and ($\pm$)-**16**, Pt 622 **4** was finally obtained in an overall yield of 5.6%.

The authors wish to thank the 'AUF Antananarivo, Région Rhône-Alpes and EGIDE Lyon' for the grant to C.R.R.'s Ph.D.

- 1 Scott J, Williams RM. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. *Chem Rev*, 2002, 102: 1669–1730

- 2 Rinehart KL, Holt TG, Fregeau NL, Perun TJ, Seigler DS, Wilson GR, Shield LS. Biologically active natural products. *Pure Appl Chem*, 1990, 62: 1277–1280
- 3 Wright AE, Forleo DA, Gunawardana GP, Gunasekera SP, Koehn FE, McConnel OJ. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian *Ecteinascidia turbinate*. *J Org Chem*, 1990, 55: 4508–4512
- 4 Rinehart KL, Holt TG, Fregeau NL, Keifer PA, Sun F, Li H, Martin DG. Ecteinascidins 729, 743, 759A, 759B and 770: Potent antitumor agents from the Caribbean tunicate *Ecteinascidia turbinate*. *J Org Chem*, 1990, 55: 4512–4515
- 5 Sakai R, Rinehart KL, Guan Y, Wang AHJ. Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structure and activities *in vivo*. *Proc Nat Acad Sci USA*, 1992, 89: 11456–11460
- 6 Sakai R, Jares-Erijaman E, Manzanares I, Elipse MV, Rinehart KL. Ecteinascidins: Putative biosynthetic precursors and absolute stereochemistry. *J Am Chem Soc*, 1996, 118: 9017–9023
- 7 Aune GJ, Furuta T, Pommier Y. Ecteinascidin 743: A novel anticancer drug with a unique mechanism of action. *Anti-Cancer Drugs*, 2002, 13: 545–555
- 8 Corey EJ, Gin, DY, Kania RS. Enantioselective total synthesis of ecteinascidin 743. *J Am Chem Soc*, 1996, 118: 9202–92203
- 9 Martinez EJ, Corey EJ. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agent. *Org Lett*, 2000, 2: 993–996
- 10 Endo A, Yanagisawa A, Abe M, Tohma S, Kan T, Fukuyama T. Total synthesis of ecteinascidin 743. *J Am Chem Soc*, 2002, 124: 6552–6554
- 11 Chen J, Chen X, Bois-Choussy M, Zhu J. Total synthesis of ecteinascidin 743. *J Am Chem Soc*, 2006, 128, 87–89
- 12 Zheng S, Chan C, Furuuchi T, Wright BJD, Zhou B, Guo J, Danishefsky SJ. Stereospecific formal total synthesis of ecteinascidin 743. *Angew Chem Int Ed*, 2006, 45: 1754–1759
- 13 Martinez EJ, Owa T, Schreiber SL, Corey EJ. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. *Proc Natl Acad Sci USA*, 1999, 96: 3496–3501
- 14 Martinez EJ, Corey EJ, Owa T. Phthalascidin, a synthetic antitumor agent with potency and mode of action. *Chem Biol*, 2001, 8: 1151–1160
- 15 Gonzales JF, Salazar L, de la Cuesta E, Avendano C. Synthesis of phthalascidin analogues. *Tetrahedron*, 2005, 61: 7447–7455
- 16 (a) Ortin I, Gonzales JF, de la Cuesta E, Manguan-Garcia C, Perona R, Avendano C. Pyrazino[1,2-b]isoquinolines: Síntesis and study of their cytostatic and cytotoxic properties. *Bioorg Med Chem*, 2008, 16: 9065–9078; (b) Ortin I, Gonzales JF, de la Cuesta E, Perona R, Avendano C. Synthesis of a novel tetrahydroisoquinoline pentacyclic framework. *Tetrahedron*, 2009, 65: 2201–2211
- 17 Cuevas C, Pérez M, Martín MJ, Chicharro JL, Fernández-Rivas C, Flores M, Francesch A, Gallego P, Zarzuelo M, de la Calle F, García J, Polanco C, Rodríguez I, Manzanares I. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafrafrin B. *Org Lett*, 2000, 2: 2545–2548
- 18 Menchaca R, Martínez V, Rodríguez A, Rodríguez N, Flores M, Gallego P, Manzanares I, Cuevas C. synthesis of natural ecteinascidins (ET-729, ET-745, ET-759B, ET-736, ET-637, ET-594) from cyanosafrafrin B. *J Org Chem*, 2003, 68: 8859–8866
- 19 Ikeda Y, Idemeto H, Hirayama F, Yamamoto K, Iwao K, Asao T, Munakata T. Safracins, new antitumor antibiotics. I. Producing organism, fermentation and isolation. *J Antibiot*, 1983, 36: 1279–1283
- 20 Myers AG, Lanman BA. A solid-supported, enantioselective synthesis suitable for the rapid preparation of large numbers of diverse structural analogues of (–)-saframycin A. *J Am Chem Soc*, 2002, 124: 12969–12971
- 21 Myers AG, Plowright AT. Synthesis and evaluation of bishydroquinone derivatives of (–)-saframycin A: Identification of a versatile molecular template imparting potent antiproliferative activity. *J Am Chem Soc*, 2001, 123: 5114–5115
- 22 Plowright AT, Schaus SE, Myers AG. Transcriptional response pathway in the yeast strain sensitive to saframycin A a more potent analog—Evidence for a common basis of activity. *Chem Biol*, 2002, 9: 607–618
- 23 Spencer JR, Sendzik M, Oeh J, Sabbatini P, Dalrymple SA, Magill C, Kim HM, Zhang SA, Squires N, Moss KG, Sukbuntherng J, Graupe D, Eksterowicz J, Young PR, Myers AG, Green MJ. Evaluation of antitumor properties of novel saframycin analogs *in vitro* and *in vivo*. *Bioorg Med Chem Lett*, 2006, 16: 4884–4888
- 24 Ong CW, Chang YA, Wu J-W, Cheng C-C. Novel design of a pentacyclic scaffold as structural mimic of saframycin A. *Tetrahedron*, 2003, 59: 8245–8249
- 25 Lane JW, Chen Y, Williams RM. Asymmetric total syntheses of (–)-jorumycin, (–)-renieramycin G, 3-*epi*-jorumycin, and 3-*epi*-renieramycin G. *J Am Chem Soc*, 2005, 127: 12684–12690
- 26 Lane JW, Estevez A, Mortara K, Callan O, Spencer JR, Williams RM. Antitumor activity of tetrahydroisoquinoline analogues 3-*epi*-jorumycin and 3-*epi*-renieramycin G. *Bioorg Med Chem Lett*, 2006, 16: 3180–3183
- 27 Tang Y-F, Liu Z-Z, Chen S-Z. A new efficient synthetic process for the construction of the pentacyclic core of marine alkaloid ecteinascidins. *Tetrahedron Lett*, 2003, 44, 7091–7094
- 28 Liu Z-Z, Wang Y, Tang Y-F, Chen S-Z, Chen X-G, Li H-Y. Synthesis and antitumor activity of simplified ecteinascidin-saframycin analogs. *Bioorg Med Chem Lett*, 2006, 16: 1282–1285
- 29 González JF, Salazar L, de la Cuesta E, Avendaño C. Synthesis of phthalascidin analogues. *Tetrahedron*, 2005, 61: 7447–7455
- 30 González JF, de la Cuesta E, Avendaño C. Synthesis and cytotoxic activity of pyrazino[1,2-], 1-(3-isoquinolyl)-isoquinoline, and 6,15-iminoisoquinolo[3,2-b]-3-benzazocines. *Bioorg Med Chem*, 2007, 15: 112–118
- 31 Ceballos PA, Pérez M, Cuevas C, Francesch A, Manzanares I, Echavarran AM. Synthesis of ecteinascidin 743 analogues from cyanosafrafrin B: Isolation of a kinetically stable quinoneimine tautomer of a 5-hydroxyindole. *Eur J Org Chem*, 2006, 1926–1933
- 32 Puthongking P, Patarapanich C, Amnuoppol S, Suwanborirux K, Kubo A, Saito N. Chemistry of ecteinascidins. Part 2. Preparation of 6'-*O*-acyl derivatives of stable ecteinascidin and evaluation of cytotoxicity. *Chem Pharm Bull*, 2006, 54: 1010–1016
- 33 Koizumi Y-I, Inamura K-I, Kubo A, Saito N. Synthesis of 1,2,3,4,5,6,7,10-octahydro-1,5-imino-7,10-dioxo-3-benzazocine-4-carbonitrile derivative and evaluation of antitumor activity related to saframycin and renieramycin isoquinolinequinones. *Heterocycles*, 2006, 70: 477–490
- 34 Gomez-Monterey IM, Campiglia P, Bertamino A, Mazzoni O, Diurno MV, Novellino E, Grieco P. A novel approach to the synthesis of diaza-bridged heterocycle derivatives. *Tetrahedron*, 2006, 62: 8083–8088
- 35 Veerman JJN, Bon RS, Hue BTB, Girones D, Rutjes FPJT, van Maarseveen JH, Hiemstra H. Synthesis of 2,6-bridged piperazine-3-ones by *N*-acyliminium ion chemistry. *J Org Chem*, 2003, 68: 4486–4494
- 36 Aubry S, Pellet-Rostaing S, Fenet R, Lemaire M. Synthetic investigation of (1,3')-bistetrahydroisoquinolines towards pentacyclic analogues of piperazine core alkaloids *Tetrahedron Lett*, 2006, 47, 1319–1323
- 37 Aubry S, Pellet-Rostaing S, Fenet R, Lemaire M. Synthesis and inhibition of cancer cell proliferation of (1,3')-bis-tetrahydroisoquinolines and piperazine systems. *Bioorg Med Chem Lett*, 2007, 7: 2598
- 38 Aubry S, Bourdon B, Razafindrabe RC, Pellet-Rostaing S, Lemaire M. Synthetic studies towards phthalascidin 650: Synthesis of a fully functionalized *N*-protected α -amino-aldehyde. *Tetrahedron Lett*, 2007, 48: 9163–9166
- 39 Cundasawmy NE, Maclean DB. The synthesis of ochrobirine. A new route to the spirobenzylisoquinoline system. *Can J Chem*, 1972, 50: 3028–3036
- 40 Chandrasekhar S, Reddy NR, Rao YS. Synthetic studies on ecteinascidin-743: Synthesis of building blocks through sharpless asymmetric dihydroxylation and aza-Michael reactions. *Tetrahedron*, 2006, 62: 12098–12107

- 41 Grosset V, Danvy D, Capet M. Determination of the absolute configuration of fasidotril, a potent dual ACE/NEP inhibitor. *Tetrahedron: Asymmetry*, 2003, 14, 2335–2237
- 42 Vilsmeier A, Haack, A. *Chem. Ber.* 1927, 60: 119–122
- 43 Knoevenagel, E. *Chem. Ber.* 1896, 29: 172–174
- 44 Lehnert W. Knoevenagel kondensationen mit titanetrachlorid/base-II: Alkyliden und arylidenacet-bzw. *Tetrahedron*, 1972, 28: 663–666
- 45 Versleijen JPG, Van Leusen AM, Feringa BL. Cooper(I) phosphoramidite catalyzed asymmetric conjugate reagents of α,β -unsaturated nitroacetate; an enantioselective route to β -aryl-nitroalkanes. *Tetrahedron Lett*, 1999, 40: 5803–5806
- 46 Cyril BD, Stanley MR. Synthesis of enantiopure 7-aminobicyclo [3.2.0]hept-2-en-6-ol; a potential N-O chelating ligand for enantioselective catalysis. *Arkivoc*, 2000, VI: 882–888
- 47 Bischler A, Napieralski B. *Ber Dtsch Chem Ges*, 1893, 26: 1903–1908
- 48 Whaley WM, Govandrichi TR. *Org React*, 1951, 6: 74–150
- 49 Roszkowski P, Maurin JK, Czarnocki Z. Enantioselective synthesis of (*R*)-(-)-praziquantel (PZQ). *Tetrahedron: Asymmetry*, 2006, 17, 1415–1419
- 50 Dess DB, Martin JC. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. *J Org Chem*, 1983, 48: 4155–4156
- 51 Dess DB, Martin JC. A useful 12-I-5 triacetoxypersulfonane (the Dess Martin persulfonane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species. *J Am Chem Soc*, 1991, 113: 7277–7287
- 52 Chen J, Chen X, Bois-Choussy M, Zhu J. Total synthesis of ecteinascidin 743. *J Am Chem Soc*, 2006, 128: 87–89
- 53 Vincent G, Lanea JW, Williams RM. Regioselectivity of Pictet-Spengler cyclization reactions to construct the pentacyclic framework of the ecteinascidin-saframycin class of tetrahydroisoquinoline antitumor antibiotics. *Tetrahedron Lett*, 2007, 48: 3719–3722
- 54 Duff JC. *J. Chem. Soc.* 1932, 1987–1991
- 55 Ferguson LN. The synthesis of aromatic aldehydes. *Chem Rev*, 1946, 38: 227–254
- 56 Ong CW, Chang YA, Wu JY, Chien-Chung Cheng CC. Novel design of pentacyclic scaffold as structural mimic of saframycin A. *Tetrahedron*, 2003, 59: 8245–8249
- 57 Chang YA, Sun TH, Chiang MY, Lu PJ, Yi-Ting Huang YT, Liang LC, Ong CW. Short synthesis of piperizinoisoquinoline ring by selective Pictet-Spengler cyclization and evaluation of antitumor activity. *Tetrahedron*, 2007, 63: 8781–8787